Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01637285
First received: June 26, 2012
Last updated: July 30, 2015
Last verified: July 2015

June 26, 2012
July 30, 2015
August 2012
January 2013   (final data collection date for primary outcome measure)
PF-04856883 Pharmacokinetics including Cmax, Tmax, AUCo-infinity, AUClast, Cl/F, Vz/F and t1/2 [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
PF-04856883 Pharmacokinetics including Cmax, Tmax, AUCo-infinity, AUClast, Cl/F, Vz/F and t1/2 [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01637285 on ClinicalTrials.gov Archive Site
  • Number of subjects with AEs reported [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with abnormal physical examination findings [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with abnormal clinical laboratory results [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with abnormal ECGs [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with abnormal vital signs [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers
A Phase 1, Randomized, Open-label, Parallel-group Study To Evaluate The Pharmacokinetics Of Pf-04856883 (Cvx-096) Following Subcutaneous Administration In Healthy Volunteers
The purpose of the study is to further evaluate the PK characteristics of PF-04856883.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Healthy
  • Biological: PF-04856883
    Dose A
  • Biological: PF-04856883
    Dose B
  • Biological: PF-04856883
    Dose C
  • Biological: PF-04856883
    Dose D
  • Experimental: PF-04856883 Treatment Arm 1
    Intervention: Biological: PF-04856883
  • Experimental: PF-04856883 Treatment Arm 2
    Intervention: Biological: PF-04856883
  • Experimental: PF-04856883 Treatment Arm 3
    Intervention: Biological: PF-04856883
  • Experimental: PF-04856883 Treatment Arm 4
    Intervention: Biological: PF-04856883
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Exclusion Criteria:

Both
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01637285
B1111005
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP